Interview with Swee-Yeok CHU, CEO & President, EDBI/Bio One Capital
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Address: 250 North Bridge Road,#28-00 Raffles City Tower, Singapore 179101,Singapore
Tel: +65 6832 6832
Web: http://www.edbi.com/
Bio One Capital is a leading strategic investment firm headquartered in Singapore with a worldwide presence investing to drive growth opportunities within the knowledge and innovation-intensive sectors of Biomedical Sciences, Clean Technologies, Internet & Digital Media, as well as other strategic industry clusters with commercial potential. As a value adding investor, they create sustainable and synergistic partnerships with their portfolio companies, leveraging on their broad network of resources and experience to facilitate the companies’ organic growth in Asia and the world, through their operations in Singapore
Investment firm
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration…
Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their…
Writing in the November 2024 edition of DIA’s Global Forum magazine, Johnson & Johnson’s Sandy Chan looks at the fast-evolving regulatory framework for medicines in the dynamic Asia-Pacific region. …
A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest…
A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the…
The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local…
As the COVID-19 pandemic showed, vaccination is perhaps the most important tool a country has in maintaining the health of its population. Writing in the May 2023 edition of DIA’s…
The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of…
The latest pharma and healthcare news from Southeast Asia, including the proposed healthcare programs of Thailand’s political parties for the upcoming election; Singapore’s approval of Pfizer’s 20-valent pneumococcal conjugate vaccine;…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants…
On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach…
See our Cookie Privacy Policy Here
